These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

101 related items for PubMed ID: 7856175

  • 1. The RED-LIP study--pravastatin in primary isolated hypercholesterolemia--an open, prospective, multicenter trial.
    Sinzinger H, Pirich C.
    Wien Klin Wochenschr; 1994; 106(23):721-7. PubMed ID: 7856175
    [Abstract] [Full Text] [Related]

  • 2. Comparison of the short-term efficacy and tolerability of lovastatin and pravastatin in the management of primary hypercholesterolemia.
    McPherson R, Bedard J, Connelly P, Curnew G, Davignon J, Echenberg D, Lavin P, Leiter L, Lenis J, McQueen M.
    Clin Ther; 1992; 14(2):276-91. PubMed ID: 1611649
    [Abstract] [Full Text] [Related]

  • 3. A comparison of estrogen replacement, pravastatin, and combined treatment for the management of hypercholesterolemia in postmenopausal women.
    Davidson MH, Testolin LM, Maki KC, von Duvillard S, Drennan KB.
    Arch Intern Med; 1997 Jun 09; 157(11):1186-92. PubMed ID: 9183229
    [Abstract] [Full Text] [Related]

  • 4. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
    Jones PH, Hunninghake DB, Ferdinand KC, Stein EA, Gold A, Caplan RJ, Blasetto JW, Statin Therapies for Elevated Lipid Levels Compared Across Doses to Rosuvastatin Study Group.
    Clin Ther; 2004 Sep 09; 26(9):1388-99. PubMed ID: 15531001
    [Abstract] [Full Text] [Related]

  • 5. Differing effects of low-dose estrogen-progestin therapy and pravastatin in postmenopausal hypercholesterolemic women.
    Davis SR, Goldstat R, Newman A, Berry K, Burger HG, Meredith I, Koch K.
    Climacteric; 2002 Dec 09; 5(4):341-50. PubMed ID: 12626213
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of pravastatin as a hypolipidemic agent in patients with polygenic hypercholesterolemia.
    Aldrete-Velasco J, Casanova JM, Mejía P, Martínez P.
    Arch Med Res; 1992 Dec 09; 23(3):117-22. PubMed ID: 1308800
    [Abstract] [Full Text] [Related]

  • 7. Tolerability and effects on lipids of ezetimibe coadministered with pravastatin or simvastatin for twelve months: results from two open-label extension studies in hypercholesterolemic patients.
    Strony J, Hoffman R, Hanson M, Veltri E.
    Clin Ther; 2008 Dec 09; 30(12):2280-97. PubMed ID: 19167588
    [Abstract] [Full Text] [Related]

  • 8. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
    Strandberg TE, Feely J, Sigurdsson EL, DISCOVERY study group.
    Clin Ther; 2004 Nov 09; 26(11):1821-33. PubMed ID: 15639694
    [Abstract] [Full Text] [Related]

  • 9. [Pravastatin in the treatment of primary hypercholesterolemia: a Swiss multicenter study].
    Ferrari P, Weidmann P, Riesen WF, Martius F, Luban S, Pasotti E, Erne P, Fragiacomo C, Noseda G, Reutter F.
    Schweiz Med Wochenschr; 1993 Sep 18; 123(37):1736-41. PubMed ID: 8211024
    [Abstract] [Full Text] [Related]

  • 10. Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia.
    Lee SH, Chung N, Kwan J, Kim DI, Kim WH, Kim CJ, Kim HS, Park SH, Seo HS, Shin DG, Shin YW, Shim WJ, Ahn TH, Ho Yun K, Yoon MH, Cha KS, Choi SW, Han SW, Hyon MS.
    Clin Ther; 2007 Nov 18; 29(11):2365-73. PubMed ID: 18158077
    [Abstract] [Full Text] [Related]

  • 11. Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study.
    Schuster H, Barter PJ, Stender S, Cheung RC, Bonnet J, Morrell JM, Watkins C, Kallend D, Raza A, Effective Reductions in Cholesterol Using Rosuvastatin Therapy I study group.
    Am Heart J; 2004 Apr 18; 147(4):705-13. PubMed ID: 15077101
    [Abstract] [Full Text] [Related]

  • 12. Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial.
    Stender S, Schuster H, Barter P, Watkins C, Kallend D, MERCURY I Study Group.
    Diabetes Obes Metab; 2005 Jul 18; 7(4):430-8. PubMed ID: 15955130
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of pravastatin once daily in primary moderate hypercholesterolemia: the Israeli experience.
    Beigel Y, Brook G, Eisenberg S, Fainaru M, Harats D, Levy Y, Rubinstein A, Skurnik Y.
    Isr J Med Sci; 1993 May 18; 29(5):272-7. PubMed ID: 8314685
    [Abstract] [Full Text] [Related]

  • 14. Comparative efficacy and safety of pravastatin and cholestyramine alone and combined in patients with hypercholesterolemia. Pravastatin Multicenter Study Group II.
    Arch Intern Med; 1993 Jun 14; 153(11):1321-9. PubMed ID: 8507122
    [Abstract] [Full Text] [Related]

  • 15. [Pravastatin vs. probucol in the treatment of hypercholesterolemia. A double-blind study].
    Sienra-Pérez JC, Lerman-Garber I, Ahumada-Ayala M, Castañón-Romo C, Cardoso-Saldaña G, Laguna-Castellanos M, Posadas-Romero C.
    Arch Inst Cardiol Mex; 1991 Jun 14; 61(4):365-73. PubMed ID: 1953212
    [Abstract] [Full Text] [Related]

  • 16. Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies.
    Glueck CJ, Aregawi D, Agloria M, Khalil Q, Winiarska M, Munjal J, Gogineni S, Wang P.
    Clin Ther; 2006 Jun 14; 28(6):933-42. PubMed ID: 16860175
    [Abstract] [Full Text] [Related]

  • 17. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
    Alvarez-Sala LA, Cachofeiro V, Masana L, Suarez C, Pinilla B, Plana N, Trias F, Moreno MA, Gambus G, Lahera V, Pintó X.
    Clin Ther; 2008 Jan 14; 30(1):84-97. PubMed ID: 18343245
    [Abstract] [Full Text] [Related]

  • 18. Beneficial effects of atorvastatin on sd LDL and LDL phenotype B in statin-naive patients and patients previously treated with simvastatin or pravastatin.
    Baldassarre S, Scruel O, Deckelbaum RJ, Dupont IE, Ducobu J, Carpentier YA.
    Int J Cardiol; 2005 Oct 10; 104(3):338-45. PubMed ID: 16186066
    [Abstract] [Full Text] [Related]

  • 19. Effects of policosanol 20 versus 40 mg/day in the treatment of patients with type II hypercholesterolemia: a 6-month double-blind study.
    Castaño G, Mas R, Fernández L, Illnait J, Gámez R, Alvarez E.
    Int J Clin Pharmacol Res; 2001 Oct 10; 21(1):43-57. PubMed ID: 11708574
    [Abstract] [Full Text] [Related]

  • 20. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin.
    Stein E, Stender S, Mata P, Sager P, Ponsonnet D, Melani L, Lipka L, Suresh R, Maccubbin D, Veltri E, Ezetimibe Study Group.
    Am Heart J; 2004 Sep 10; 148(3):447-55. PubMed ID: 15389231
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.